Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03830320

Positron Emission Tomography (PET) Imaging of Thrombosis

Preliminary Evaluation of [64Cu]FBP8 in Healthy Individuals and Subjects With Known or at Risk of Developing Thrombosis

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
165 (estimated)
Sponsor
Massachusetts General Hospital · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of patients with atrial fibrillation, and thereby may provide a non-invasive alternative to the current standard-of-care methods.

Detailed description

The primary objectives of this study are: 1. To evaluate the safety of \[64Cu\]FBP8 and its whole body distribution, metabolism, pharmacokinetics, and radiation burden in healthy volunteers. 2. To establish the accuracy of \[64Cu\]FBP8 -PET to detect left atrial thrombosis in patients with atrial fibrillation. 3. To explore the feasibility of \[64Cu\]FBP8 -PET to detect thrombosis in patients with COVID-19. 4. To explore the feasibility of \[64Cu\]FBP8 -PET to detect thrombosis in patients with cancer. 5. To explore the feasibility of \[64Cu\]FBP8 -PET to detect thrombosis in patients with known or suspicion of thrombus outside of the left atrial appendage.

Conditions

Interventions

TypeNameDescription
DRUG[64Cu]FBP8Injection of Copper-64 radiopeptide to detect thrombosis
DEVICEPET/MRWhole body imaging using Siemens mMR PET/MR scanner
PROCEDUREBlood CollectionA total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
PROCEDUREElectrocardiogramA standard 12-lead ECG will be obtained pre-and-post injection with radiotracer

Timeline

Start date
2016-04-01
Primary completion
2027-01-31
Completion
2027-01-31
First posted
2019-02-05
Last updated
2026-02-27

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03830320. Inclusion in this directory is not an endorsement.